Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dusan Stefoski

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Annals of Clinical and Translational Neurology|July 12, 2017
Glioblastoma in natalizumab-treated multiple sclerosis patientsFabian Sierra Morales, Robert B Wright, Jorge E Novo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 10, 2011
Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitisZhihua Ren, Yan Wang, Duan Tao, et al.
Neurology and Therapy|July 15, 2016
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study ProgramRalf Gold, Dusan Stefoski, Krzysztof Selmaj, et al.
Journal of Neuroimmunology|May 19, 2009
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosisClaudia C Kaiser, Dinesh K Shukla, Glenn T Stebbins, et al.
Journal of the Neurological Sciences|January 13, 2010
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosisThomas Liggett, Anatoliy Melnikov, Shilpa Tilwalli, et al.
The Lancet. Neurology|March 25, 2014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Ralf Gold, Krzysztof Selmaj, et al.
Blood|November 23, 2006
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen usedYvonne Loh, Yu Oyama, Laisvyde Statkute, et al.
Lancet (London, England)|April 9, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gavin Giovannoni, Krzysztof Selmaj, et al.
BMC Neurology|July 28, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studyRalf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Annals of Clinical and Translational Neurology|July 12, 2017
Glioblastoma in natalizumab-treated multiple sclerosis patientsFabian Sierra Morales, Robert B Wright, Jorge E Novo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 10, 2011
Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitisZhihua Ren, Yan Wang, Duan Tao, et al.
Neurology and Therapy|July 15, 2016
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study ProgramRalf Gold, Dusan Stefoski, Krzysztof Selmaj, et al.
Journal of Neuroimmunology|May 19, 2009
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosisClaudia C Kaiser, Dinesh K Shukla, Glenn T Stebbins, et al.
Journal of the Neurological Sciences|January 13, 2010
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosisThomas Liggett, Anatoliy Melnikov, Shilpa Tilwalli, et al.
The Lancet. Neurology|March 25, 2014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Ralf Gold, Krzysztof Selmaj, et al.
Blood|November 23, 2006
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen usedYvonne Loh, Yu Oyama, Laisvyde Statkute, et al.
Lancet (London, England)|April 9, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gavin Giovannoni, Krzysztof Selmaj, et al.
BMC Neurology|July 28, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studyRalf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Pageof 3